Development, Strategies, and Challenges for Tularemia Vaccine
- PMID: 38564047
- DOI: 10.1007/s00284-024-03658-0
Development, Strategies, and Challenges for Tularemia Vaccine
Abstract
Francisella tularensis is a facultative intracellular bacterial pathogen that affects both humans and animals. It was developed into a biological warfare weapon as a result. In this article, the current status of tularemia vaccine development is presented. A live-attenuated vaccine that was designed over 50 years ago using the less virulent F. tularensis subspecies holarctica is the only prophylactic currently available, but it has not been approved for use in humans or animals. Other promising live, killed, and subunit vaccine candidates have recently been developed and tested in animal models. This study will investigate some possible vaccines and the challenges they face during development.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.Front Cell Infect Microbiol. 2018 May 15;8:154. doi: 10.3389/fcimb.2018.00154. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 29868510 Free PMC article. Review.
-
Tularemia vaccines: recent developments and remaining hurdles.Future Microbiol. 2011 Apr;6(4):391-405. doi: 10.2217/fmb.11.22. Future Microbiol. 2011. PMID: 21526941 Review.
-
A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.PLoS One. 2013 Nov 13;8(11):e78671. doi: 10.1371/journal.pone.0078671. eCollection 2013. PLoS One. 2013. PMID: 24236032 Free PMC article.
-
Vaccines against Francisella tularensis.Ann N Y Acad Sci. 2007 Jun;1105:325-50. doi: 10.1196/annals.1409.012. Epub 2007 Mar 29. Ann N Y Acad Sci. 2007. PMID: 17395730 Review.
-
Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria.Mol Immunol. 2013 May;54(1):58-67. doi: 10.1016/j.molimm.2012.10.043. Epub 2012 Nov 28. Mol Immunol. 2013. PMID: 23201853
Cited by
-
Global resurgence of tularemia: Challenges and strategic public health imperatives.New Microbes New Infect. 2025 Jun 2;66:101605. doi: 10.1016/j.nmni.2025.101605. eCollection 2025 Aug. New Microbes New Infect. 2025. PMID: 40538740 Free PMC article. No abstract available.
-
Development of a multi-epitope vaccine from outer membrane proteins and identification of novel drug targets against Francisella tularensis: an In Silico approach.Front Immunol. 2025 Apr 3;16:1479862. doi: 10.3389/fimmu.2025.1479862. eCollection 2025. Front Immunol. 2025. PMID: 40248715 Free PMC article.
References
-
- Flora S (2020) Biological warfare agents: history and modern-day relevance. Handbook on biological warfare preparedness. Elsevier, Amsterdam, pp 1–11. https://doi.org/10.1016/B978-0-12-812026-2.00001-3 - DOI
-
- Sunagar R et al (2016) Tularemia vaccine development: paralysis or progress? Vaccine (Auckl) 6:9–23. https://doi.org/10.2147/vdt.S85545 - DOI - PubMed
-
- Oyston PC, Quarry JE (2005) Tularemia vaccine: past, present and future. Antonie Van Leeuwenhoek 87(4):277–281. https://doi.org/10.1016/B978-0-12-812026-2.00001-3 - DOI - PubMed
-
- Maurin M et al (2024) Tularemia treatment: experimental and clinical data. Front Microbiol 14:1348323. https://doi.org/10.3389/fmicb.2023.1348323 - DOI - PubMed - PMC
-
- Maurin M, Gyuranecz M (2016) Tularaemia: clinical aspects in Europe. Lancet Infect Dis 16(1):113–124. https://doi.org/10.1016/S1473-3099(15)00355-2 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical